According to the Cambridge-based technology company, the new module enables investigators to digitally annotate and e-sign lab reports and other PDFs.
“Digitalizing lab reports enables PI's [principal investigators] to sign off remotely, meaning they facilitate PI oversight because it de-couples work from location,” Raymond Nomizu, JD, Co-Founder and Co-CEO of CRIO, told Outsourcing-Pharma.com.
With CRIO’s system, Nomizu explained PIs can access a single website to see labs, annotate and e-sign them, access other patient information, and communicate privately with coordinators.
“In current paper-based workflows that are prevalent in non-oncology trials, coordinators have to print out hard copies, then track down the PI for wet-ink signature, then put the copies back into the binder,” he said. “If the PI wants to retrieve the labs for later review, he/she has to physically grab a paper binder and flip open the pages to find the lab in question.”
CRIO launched in September of last year and has deployed its technology in more than 60 studies.